359 related articles for article (PubMed ID: 29909239)
1. Approaches to target IgE antibodies in allergic diseases.
Balbino B; Conde E; Marichal T; Starkl P; Reber LL
Pharmacol Ther; 2018 Nov; 191():50-64. PubMed ID: 29909239
[TBL] [Abstract][Full Text] [Related]
2. Anti-IgE monoclonal antibody (omalizumab) in the treatment of atopic asthma and allergic respiratory diseases.
D'Amato G; Liccardi G; Noschese P; Salzillo A; D'Amato M; Cazzola M
Curr Drug Targets Inflamm Allergy; 2004 Sep; 3(3):227-9. PubMed ID: 15379589
[TBL] [Abstract][Full Text] [Related]
3. Current Strategies to Inhibit High Affinity FcεRI-Mediated Signaling for the Treatment of Allergic Disease.
Gomez G
Front Immunol; 2019; 10():175. PubMed ID: 30792720
[TBL] [Abstract][Full Text] [Related]
4. The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab.
Gasser P; Tarchevskaya SS; Guntern P; Brigger D; Ruppli R; Zbären N; Kleinboelting S; Heusser C; Jardetzky TS; Eggel A
Nat Commun; 2020 Jan; 11(1):165. PubMed ID: 31913280
[TBL] [Abstract][Full Text] [Related]
5. IgE-Related Chronic Diseases and Anti-IgE-Based Treatments.
Navinés-Ferrer A; Serrano-Candelas E; Molina-Molina GJ; Martín M
J Immunol Res; 2016; 2016():8163803. PubMed ID: 28097159
[TBL] [Abstract][Full Text] [Related]
6. Role of anti-IgE monoclonal antibody (omalizumab) in the treatment of bronchial asthma and allergic respiratory diseases.
D'Amato G
Eur J Pharmacol; 2006 Mar; 533(1-3):302-7. PubMed ID: 16464445
[TBL] [Abstract][Full Text] [Related]
7. The use of anti-IgE therapy beyond allergic asthma.
Stokes JR; Casale TB
J Allergy Clin Immunol Pract; 2015; 3(2):162-6. PubMed ID: 25609342
[TBL] [Abstract][Full Text] [Related]
8. Omalizumab beyond asthma.
Sanchez J; Ramirez R; Diez S; Sus S; Echenique A; Olivares M; Cardona R
Allergol Immunopathol (Madr); 2012; 40(5):306-15. PubMed ID: 22264640
[TBL] [Abstract][Full Text] [Related]
9. Vaccines targeting IgE in the treatment of asthma and allergy.
Peng Z
Hum Vaccin; 2009 May; 5(5):302-9. PubMed ID: 19221515
[TBL] [Abstract][Full Text] [Related]
10. Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases.
Chang TW; Wu PC; Hsu CL; Hung AF
Adv Immunol; 2007; 93():63-119. PubMed ID: 17383539
[TBL] [Abstract][Full Text] [Related]
11. Omalizumab: not only for asthma.
Ben-Shoshan M
Recent Pat Inflamm Allergy Drug Discov; 2008 Nov; 2(3):191-201. PubMed ID: 19076009
[TBL] [Abstract][Full Text] [Related]
12. Qualitative effects of omalizumab on concomitant IgE-mediated disease in a severe asthmatic population: a real life observational study.
Cusack RP; Sahadevan A; Lane SJ
QJM; 2016 Sep; 109(9):601-4. PubMed ID: 26966102
[TBL] [Abstract][Full Text] [Related]
13. The discovery and development of omalizumab for the treatment of asthma.
Licari A; Marseglia G; Castagnoli R; Marseglia A; Ciprandi G
Expert Opin Drug Discov; 2015; 10(9):1033-42. PubMed ID: 25979110
[TBL] [Abstract][Full Text] [Related]
14. The anti-IgE antibody omalizumab as a probe to investigate the role of IgE in pathology.
Mauro M; Incorvaia C; Formigoni C; Elia R; Russello M; Pellegrino D
Panminerva Med; 2012 Dec; 54(4):305-12. PubMed ID: 23123583
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria.
Kaplan AP; Giménez-Arnau AM; Saini SS
Allergy; 2017 Apr; 72(4):519-533. PubMed ID: 27861988
[TBL] [Abstract][Full Text] [Related]
16. Anti-IgE monoclonal antibody: a new approach to the treatment of allergic respiratory diseases.
D'Amato G; Oldani V; Donner CF
Monaldi Arch Chest Dis; 2003; 59(1):25-9. PubMed ID: 14533279
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, Pharmacodynamics, and Safety of MEDI4212, an Anti-IgE Monoclonal Antibody, in Subjects with Atopy: A Phase I Study.
Sheldon E; Schwickart M; Li J; Kim K; Crouch S; Parveen S; Kell C; Birrell C
Adv Ther; 2016 Feb; 33(2):225-51. PubMed ID: 26843086
[TBL] [Abstract][Full Text] [Related]
18. [Progress in the study of allergic disease drugs targeting on IgE/FcepsilonRI signaling pathway].
Liu ZC; Shi HL; Zhang YF; Zhao LJ
Yao Xue Xue Bao; 2011 Oct; 46(10):1161-6. PubMed ID: 22242444
[TBL] [Abstract][Full Text] [Related]
19. Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin.
Metz M; Staubach P; Bauer A; Brehler R; Gericke J; Kangas M; Ashton-Chess J; Jarvis P; Georgiou P; Canvin J; Hillenbrand R; Erpenbeck VJ; Maurer M
Theranostics; 2017; 7(5):1266-1276. PubMed ID: 28435464
[No Abstract] [Full Text] [Related]
20. Omalizumab in allergic diseases, a recent review.
Vichyanond P
Asian Pac J Allergy Immunol; 2011 Sep; 29(3):209-19. PubMed ID: 22053590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
